TD Asset Management Inc Has $948,000 Position in BioMarin Pharmaceutical Inc. $BMRN

TD Asset Management Inc lessened its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 50.9% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,241 shares of the biotechnology company’s stock after selling 17,881 shares during the quarter. TD Asset Management Inc’s holdings in BioMarin Pharmaceutical were worth $948,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of BMRN. Nuveen LLC bought a new position in shares of BioMarin Pharmaceutical in the first quarter valued at approximately $184,475,000. AQR Capital Management LLC lifted its holdings in shares of BioMarin Pharmaceutical by 127.9% in the first quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company’s stock valued at $203,987,000 after purchasing an additional 1,642,206 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 212.7% in the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock valued at $112,607,000 after purchasing an additional 1,083,512 shares in the last quarter. Fuller & Thaler Asset Management Inc. bought a new position in shares of BioMarin Pharmaceutical in the first quarter valued at approximately $59,125,000. Finally, Robeco Institutional Asset Management B.V. lifted its holdings in shares of BioMarin Pharmaceutical by 559.8% in the second quarter. Robeco Institutional Asset Management B.V. now owns 641,718 shares of the biotechnology company’s stock valued at $35,275,000 after purchasing an additional 544,457 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $53.37 on Thursday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.56 and a quick ratio of 3.60. The business has a fifty day simple moving average of $55.42 and a two-hundred day simple moving average of $57.32. BioMarin Pharmaceutical Inc. has a 1 year low of $51.56 and a 1 year high of $73.51. The company has a market capitalization of $10.25 billion, a P/E ratio of 15.84, a P/E/G ratio of 0.68 and a beta of 0.33.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Wedbush restated an “outperform” rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday, August 5th. Raymond James Financial began coverage on BioMarin Pharmaceutical in a report on Wednesday, September 3rd. They set an “outperform” rating and a $85.00 price target on the stock. Morgan Stanley dropped their price target on BioMarin Pharmaceutical from $97.00 to $96.00 and set an “overweight” rating on the stock in a report on Tuesday, July 22nd. JPMorgan Chase & Co. lifted their price target on BioMarin Pharmaceutical from $116.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Finally, Zacks Research lowered BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Thirteen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $93.26.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.